Systemic therapy options for advanced bladder cancer continue to expand. The approvals of new therapies or combinations of therapies and emerging clinical trial data continue to impact the treatment landscape, and education on the topic would be valuable to help clinicians stay up to date with the latest research

Despite recent advances in immunotherapies and targeted therapies for patients with advanced melanoma, treatment options are at times limited by the availability of reliable molecular markers, development of drug resistance, and the need for better early diagnosis. An overview of current challenges facing this patient population, as well as an in-depth analysis of treatment modalities, will benefit clinicians in selecting treatment options for patients with melanoma.

While the prognosis for patients with squamous and basal cell skin cancer is generally good, current treatment recommendations are limited by the risk status classifications and associated available treatment options. There are subsets of patients who are prone to recurrence or regional and distant metastasis. Awareness of these disease features is crucial to identifying such patients and performing the appropriate treatment, especially as new regimens become available.

Cancer drug shortages have had a significant impact on clinical practice with much confusion around how to appropriately manage care of patients with cancer in the midst of a drug shortage. You can benefit by learning what you can do both in your practice and in your advocacy to advance short-term and long-term solutions.